Loading...
Loading...
RCKT| Name | Value |
|---|---|
| Revenues | 10.3M |
| Cost of Revenue | 5.2M |
| Gross Profit | 5.2M |
| Operating Expense | 63.3M |
| Operating I/L | -63.3M |
| Other Income/Expense | 3.6M |
| Interest Income | 4.1M |
| Pretax | -59.7M |
| Income Tax Expense | 1.6M |
| Net Income/Loss | -59.7M |
Rocket Pharmaceuticals, Inc. is a multi-platform biotechnology company specializing in gene therapies for rare diseases. The company's revenue is generated through its three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, leukocyte adhesion deficiency-I, and pyruvate kinase deficiency, as well as a clinical stage in vivo adeno-associated virus program for Danon disease. Rocket Pharmaceuticals, Inc. also has license agreements with various research institutions and companies to further develop and commercialize its gene therapy products.
